Wall Street Zen upgraded shares of Seaport Therapeutics (NASDAQ:SPTX – Free Report) to a hold rating in a research report sent to investors on Saturday.
Seaport Therapeutics Stock Performance
Seaport Therapeutics stock opened at $15.25 on Friday. Seaport Therapeutics has a 12 month low of $14.85 and a 12 month high of $23.00.
Insider Buying and Selling at Seaport Therapeutics
In other Seaport Therapeutics news, major shareholder Arch Venture Partners Xii, Llc bought 1,100,000 shares of Seaport Therapeutics stock in a transaction on Monday, May 4th. The shares were purchased at an average price of $18.00 per share, with a total value of $19,800,000.00. Following the acquisition, the insider owned 6,294,951 shares in the company, valued at $113,309,118. This trade represents a 21.17% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Featured Stories
- Five stocks we like better than Seaport Therapeutics
- Before the Moon Base Gets Built, These 4 Companies Win
- Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases
- 3 Stocks That Win If Inflation Surprises to the Downside
- MercadoLibre Boldly Invests in Growth: Discount Deepens
Receive News & Ratings for Seaport Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seaport Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
